Provided by Tiger Trade Technology Pte. Ltd.

Halozyme Therapeutics

110.42
+0.58000.53%
Post-market: 111.350.9328+0.84%19:55 EDT
Volume:1.85M
Turnover:205.31M
Market Cap:12.53B
PE:32.65
High:112.65
Open:109.70
Low:109.70
Close:109.84
52wk High:116.85
52wk Low:61.23
Shares:113.50M
Float Shares:112.00M
Volume Ratio:0.85
T/O Rate:1.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.38
EPS(LYR):2.56
ROE:173.67%
ROA:25.49%
PB:87.31
PE(LYR):43.13

Loading ...

Halozyme Therapeutics (HALO) Adds Jim Daly As Valuation Questions Follow

Simply Wall St.
·
Oct 04

Halozyme Names James M. Daly as Director

Reuters
·
Oct 03

Halozyme Director Matthew L. Posard Sells USD 569,752 Common Shares

Reuters
·
Oct 03

Halozyme Appoints Jim Daly to Board of Directors

Reuters
·
Oct 01

Halozyme Announces Appointment of Jim Daly to Its Board of Directors

THOMSON REUTERS
·
Oct 01

Halozyme Prices USD 1.5 Billion 1.5% Convertible Senior Notes Due 2033

Reuters
·
Sep 23

U.S. Stocks on the MOVE-Halozyme Therapeutics, Etsy, Netflix

Reuters
·
Sep 18

Halozyme Therapeutics Hits Fresh Record After Increased $1.3 Bln Convertible Bond Sale

Reuters
·
Sep 18

Halozyme Prices Upsized USD 1.3 Billion Convertible Senior Notes Offering Due 2033

Reuters
·
Sep 18

Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes Due 2033

THOMSON REUTERS
·
Sep 18

Halozyme Director Matthew L. Posard Disposes of Common Shares Worth USD 2.02 Million

Reuters
·
Sep 18

Halozyme Therapeutics Slips on $1.05 Bln Convertible Offering Plans

Reuters
·
Sep 17

Halozyme announces proposed offering of $1.05B of 2033 convertible senior notes

TIPRANKS
·
Sep 17

Halozyme Plans USD 1.05 Billion Convertible Senior Notes Offering Due 2033

Reuters
·
Sep 17

Halozyme Therapeutics, - Expects to Use Net Proceeds to Repurchase Outstanding 2027 and 2028 Convertible Notes

THOMSON REUTERS
·
Sep 17

Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes Due 2033

THOMSON REUTERS
·
Sep 17

Halozyme CEO Helen Torley Reports Disposal of Common Shares Worth USD 6.5 Million

Reuters
·
Sep 12

Analysts’ Top NA Picks: High Roller Technologies, Inc. (ROLR), Halozyme (HALO)

TIPRANKS
·
Sep 03

H.C. Wainwright views Novartis, Alteogen pact as negative for Halozyme

TIPRANKS
·
Sep 03

Halozyme CEO, CFO to Speak at Wells Fargo Healthcare Conference Fireside Chat

Reuters
·
Sep 02